1. At a Glance
There are companies where numbers tell a clean story.
Then there are companies like Piramal Pharma, where numbers argue with management.
Revenue declined 3% in FY26 to ₹8,869 crore. EBITDA dropped 28% to ₹1,135 crore. PAT slipped into a ₹326 crore loss after exceptional charges. ROCE sits at a modest 3%. Debt remains heavy at ₹4,140 crore net debt. On the surface, this looks like a company stuck in a pharmaceutical swamp.
But then the detective in an investor starts noticing strange things.
Operating cash flow jumped to ₹1,653 crore.
Free cash flow surged to ₹776 crore.
Consumer healthcare grew 17%.
Hospital generics grew despite supply issues.
CDMO order inflows reportedly revived in H2.
Customer audits hit record highs.
And management is not talking survival.
They are talking acceleration.
That is where things become interesting.
Because troubled businesses usually hide.
This one is spending.
US$94 million capex in a weak year.
US expansion continues.
Kenalog acquisition added.
ADC capacities being expanded.
And management keeps insisting FY26 was a “transitional year,” not structural deterioration.
Whenever management uses the word transition, investors should become suspicious.
Transition can mean turning point.
It can also mean polite corporate language for “please wait another two years.”
Which one is this?
That is the puzzle.
Piramal today looks like three businesses stitched together:
A global CDMO with high aspirations but cyclicality.
A niche critical care generics franchise with enviable positions.
A consumer healthcare business quietly compounding in the background.
Individually, these can be attractive.
Together, execution becomes everything.
And then comes the real contradiction.
Markets are valuing this at roughly ₹21,297 crore while annual sales are ₹8,869 crore.
EV/EBITDA sits around 21.6.
That is not distressed valuation.
That suggests market still believes recovery is coming.
Why?
Maybe because biopharma funding recovery could revive CDMO.
Maybe because CHG margins can improve.
Maybe because consumer healthcare may be more valuable than currently recognized.
Or maybe the market is simply paying for the Piramal name.
Which is it?
That is where this gets interesting enough to read further.
Because this is not a simple growth story.
This is a forensic story.
A turnaround wrapped inside a pharma conglomerate.
And those are often where disproportionate outcomes hide.
Question for readers:
When a company has weak earnings but strong operating cash flow, is it broken — or being misread?
Let us investigate.
2. Introduction
Piramal Pharma is a curious creature.
It does not behave like a typical Indian pharma company.
It is not a straightforward formulation exporter.
It is not a pure CDMO.
It is not exactly a consumer products business.
It is a hybrid.
And hybrids often confuse markets.
The company emerged from years of acquisitions, portfolio reshaping and eventual demerger.
That history matters.
Because when investors see messy financial statements, often history explains why.
This is not a promoter who built one factory and kept adding machines.
This is a group that built through deals.
Fifteen acquisitions integrated over ten years.
That can create moats.
It can also create accounting.
Sometimes too much accounting.
What makes Piramal interesting is not what it earns today.
It is what parts of the business may be worth separately.
CDMO alone has 15 sites.
CHG has niche leadership.
Consumer healthcare has quietly crossed ₹1,274 crore.
Hidden sum-of-parts stories often get ignored.
Until they don’t.
Yet this is no fairy tale.
Debt exists.
Interest coverage at 1.06 is uncomfortable.
Inventory days have ballooned.
Recent environmental trouble at Dahej reminds everyone pharma risks are not theoretical.
FDA observations exist.
Execution risks are real.
This is why the stock feels like a courtroom case.
Bull case and bear case both have evidence.
Bull says:
Temporary pain.
Order recovery.
Operating leverage.
Margin rebound.
Bear says:
Too much debt.
Too much hope.
Too much “next year.”
And history teaches one thing.
Markets pay handsomely for recovery.
But punish delayed recovery mercilessly.
Management did say in Jan 2026 that RFP momentum was improving and overseas assets had operating leverage waiting to flip. Q4 commentary broadly supports they did partially walk that talk, especially in Q4 sequential recovery.
That matters.
Because management promises without evidence are poetry.
Management promises with early evidence become thesis.
Are we seeing thesis formation?
Or just another pharma mirage?
Keep reading.
3. Business Model – What Do They Even Do?
Let us simplify the empire.
CDMO
Other people invent molecules.
Piramal helps make them.
In simple terms?
They are a high-end pharmaceutical contractor.
But unlike commodity outsourcing, parts of this business involve sticky specialized chemistry.
ADCs.
HPAPIs.
Sterile injectables.
Peptides.
Very few casual tourists enter these businesses.
That is good.
But CDMO has mood swings.
When biotech funding is booming, everyone wants manufacturing.
When funding freezes, pipelines slow.
Piramal has felt that.
This segment is basically selling shovels in a biotech gold rush.
Problem is sometimes miners stop digging.
Complex Hospital Generics
This business feels more defensive.
Anesthesia.
Intrathecal therapy.
Injectable pain.
Niche products.
Limited
